Chiron Corporation (CHIR) FLUVIRIN Vaccine License Reinstated By UK Regulatory Agency
10/19/2005 5:12:53 PM
EMERYVILLE, Calif.--(BUSINESS WIRE)--March 2, 2005--
Chiron Corporation (Nasdaq:CHIR) today announced that it has received notice from the UK Medicines and Healthcare products Regulatory Agency (MHRA) that the agency has lifted the license suspension for Chiron's Liverpool manufacturing facility, which produces FLUVIRIN(R) influenza virus vaccine.
The notice, which follows MHRA inspections of the Liverpool facility, states that "it is the opinion of the Licensing Authority that (Chiron is) now in a position to conduct (its) operations in accordance with the principles and guidelines of Good Manufacturing Practices (GMP)." The decision is conditioned on the understanding that Chiron's high level of commitment to the completion of its remediation plan and ongoing improvements will continue. Chiron will provide the MHRA with regular weekly updates to ensure that progress on its various projects proceeds satisfactorily, and the MHRA may conduct further inspections. Chiron now has clearance to initiate full production of FLUVIRIN vaccine.
comments powered by